Strategic Partnership with Tecan and Repado
| Stock | Genetic Signatures Ltd (GSS.ASX) |
|---|---|
| Release Time | 22 Jul 2025, 8:38 a.m. |
| Price Sensitive | Yes |
Genetic Signatures Announces Strategic Partnership
- Partnership with Tecan and Repado to deliver enhanced, scalable, fully automated infectious disease testing solutions
- Developing a scalable suite of fully automated diagnostic platforms for syndromic testing laboratories
- Combining Tecan's automation, Repado's software, and Genetic Signatures' assay portfolio
Genetic Signatures, a global molecular diagnostics company, has announced a strategic partnership with Tecan, a world-renowned provider of laboratory automation solutions, and Repado, a leading developer of compliant IVD software platforms. The partnership aims to deliver an enhanced automated solution to the market, with the first phase of the project already commenced. The partnership will enable the development of a scalable suite of fully automated diagnostic platforms designed for syndromic testing laboratories. These systems will seamlessly integrate Tecan's scalable liquid handling platforms, Repado's modular, configurable software built specifically for IVD regulatory standards, and Genetic Signatures' infectious disease assay portfolio, initially including Respiratory, Gastrointestinal, and Sexually Transmitted Infection panels. The new platform will deliver automation of complex molecular workflows, reducing hands-on time and operator error, as well as regulatory-ready design aligned with IVDR, FDA, and ISO 13485 standards, and flexible deployment across central labs, hospital networks, and global distribution partners.
The first concept systems are currently in development with early access planned for select global reference labs and clinical partners. This collaboration represents a significant leap forward for Genetic Signatures in offering consolidated infectious disease testing. The solution will enable laboratory efficiencies, complete automation and regulatory compliance. Genetic Signatures has also initiated a comprehensive development program to support the expansion of its 3base® technology syndromic infectious disease menu, which will be launched alongside the new integrated hardware and software solution.